

Full list of Eisai presentations at ESMO 2025

Cancer Type	Study / Compound	Presentation Title	Presentation Type & Details
Gynecologic Cancer	Study 309 / KEYNOTE-775	Lenvatinib plus pembrolizumab (L+P) vs treatment of physician's choice (TPC) for advanced endometrial cancer (EC): 5-Year outcomes from Study 309/KEYNOTE-775	Poster Session — #1119P — Oct 18, 2025
	LEAP-001	First-line lenvatinib + pembrolizumab (L+P) vs chemotherapy (CT) for advanced or recurrent endometrial cancer (EC): additional 1-year follow-up results from ENGOT-en9/LEAP-001	Poster Session — #1114P — Oct 18, 2025
	Study 309 + LEAP-001	Lenvatinib + pembrolizumab (L+P) in advanced/recurrent endometrial cancer: Study 309/KEYNOTE-775 and ENGOT-en9/LEAP-001 post-(neo)adjuvant therapy outcomes	Poster Session — #1124P — Oct 18, 2025
Gastrointestinal Cancer	LEAP-014	Lenvatinib + pembrolizumab and chemotherapy vs pembrolizumab and chemotherapy in untreated metastatic esophageal squamous cell carcinoma: Phase III LEAP-014	Proffered Paper — #LBA79 — Oct 17, 2025, 2:40–2:50 PM
Genitourinary Cancer	CLEAR	Final analysis of lenvatinib + pembrolizumab (L+P) vs sunitinib (S) in advanced renal cell carcinoma (aRCC) with/without bone metastases	Poster Session — #2603P — Oct 18, 2025
Pipeline — Gynecologic Cancer	E7386*2	Clinical and biomarker results from E7386 Study 102: global dose-expansion cohort of E7386 + lenvatinib in advanced/recurrent endometrial cancer (aEC) that progressed on platinum-based chemotherapy and anti-PD-(L)1 immunotherapy	Poster Session — #1153P — Oct 18, 2025
Genitourinary Cancer (MSD-sponsored)	LITESPARK-010	Belzutifan + lenvatinib in Chinese patients with previously treated advanced clear cell RCC (ccRCC): updated results of cohort 1	Poster Session — #2615P — Oct 18, 2025
	KEYMAKER-U03A	First-line pembrolizumab-based regimens for advanced clear cell RCC: KEYMAKER-U03 substudy 03A	Proffered Paper — #LBA96 — Oct 18, 2025, 8:30–8:40 AM
Melanoma	KEYMAKER-U02B	First-line pembrolizumab alone or with investigational agents for advanced melanoma: updated results from Phase 1/2 KEYMAKER-U02 substudy 02B	Poster Session — #1621P — Oct 20, 2025